AGLE: NASDAQ; Engineered human therapeutic enzymes addressing rare genetic diseases and oncology

Aileron Therpeutics

CAMBRIDGE, MA

The Stapled Peptide Company: pioneering a new therapeutic modality to treat cancer and other diseases

Cavion

CHARTLOTTESVILLE, VA

Novel Cav3 ion channel modulators for a spectrum of neurological disorders

Coherus Biosciences

REDWOOD CITY, CA

CHRS: NASDAQ; Only stand-alone U.S. developer of high-quality biosimilar therapeutics

esanex

INDIANAPOLIS, IN

Clinical development of Hsp90 inhibitors in oncology

Forma Therapeutics

CAMBRIDGE, MA

Fully integrated R&D company developing best-in-class therapeutics for cancer and other serious diseases

Hydra Biosciences

CAMBRIDGE, MA

Leveraging propietary knowledge in TRP ion channels to develop drugs in neuroscience and other indications

InCube Ventures

SAN JOSE, CA

Venture firm investing in drug delivery combinations, implantable and interventional devices, and novel biomaterials

Innocrin

DURHAM, NC

Oral selective inhibitors of CYP17 lyase for the treatment of advanced breast and prostate cancer

Lysomal Therapeutics

CAMBRIDGE, MA

Developing highly selective drugs to lysosomal targets for neurodegenerative diseases

Nimbus Therapeutics

CAMBRIDGE, MA

Designing breakthrough medicines through integration of computational chemistry and biology

PTGX: NASDAQ; Stable, orally-available peptide therapeutics for the treatment of gastrointestinal and other diseases

Surface Oncology

CAMBRIDGE, MA

Beyond checkpoint inhibitors: therapeutic alteration of the tumor microenvironment

Sutro Biopharma

SAN FRANCISCO, CA

Best-in-Class and first-in-class protein and bioconjugate therapeutics through Cell-Free Synthesis

Symic Biomedical

SAN FRANCISCO, CA

Disease intervention using intrinsically synergistic biotherapeutics to modulate the extracellular matrix

Viamet Pharmaceuticals

MORRISVILLE, NC

Breakthrough therapies based on leadership and expertise in metalloenzyme chemistry and biology